Deciphering novel chemotherapy and its impact on dentistry

[1]  J. Cheong.  Tyrosine Kinase Inhibitor , 2020, Definitions.

[2]  Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.

[3]  Wed,et al.  August 2019 , 2019, TAPPI Journal.

[4]  V. Patel,et al.  Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review. , 2019, Oral surgery, oral medicine, oral pathology and oral radiology.

[5]  R. Taichman,et al.  Periodontal Treatment in Cancer Patients: an Interdisciplinary Approach , 2018, Current Oral Health Reports.

[6]  J. Mansi,et al.  MRONJ risk of adjuvant bisphosphonates in early stage breast cancer , 2017, BDJ.

[7]  E. Maiorano,et al.  A Case of Osteonecrosis of the Jaw in a Patient with Crohn’s Disease Treated with Infliximab , 2017, The American journal of case reports.

[8]  F. Jardin,et al.  Osteonecrosis of the Jaw in a Patient Presenting With Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report. , 2017, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[9]  Mark Hudson,et al.  Guidelines on the management of abnormal liver blood tests , 2017, Gut.

[10]  A. Grauer,et al.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.

[11]  M. Stiborová,et al.  Histone Deacetylase Inhibitors as Anticancer Drugs , 2017, International journal of molecular sciences.

[12]  P. Zarringhalam,et al.  Medication-related osteonecrosis of the jaw associated with aflibercept. , 2017, The British journal of oral & maxillofacial surgery.

[13]  M. Rossi,et al.  A rare case of osteonecrosis of the jaw related to imatinib , 2017, Journal of the Korean Association of Oral and Maxillofacial Surgeons.

[14]  Jingwu Xie,et al.  Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas , 2017, OncoTargets and therapy.

[15]  D. Yamamoto,et al.  Osteonecrosis of the jaw associated with everolimus: A case report. , 2017, Molecular and clinical oncology.

[16]  R. Orlowski,et al.  Proteasome inhibitors in cancer therapy , 2017, Nature Reviews Clinical Oncology.

[17]  J. Harding.  Dental care of cancer patients before , during and after treatment , 2017 .

[18]  L. Fanchini,et al.  Jaw Osteonecrosis associated with Aflibercept, Irinotecan and Fluorouracil: Attention to Oral District , 2016, Tumori.

[19]  V. Fusco,et al.  Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases , 2016, Dentistry journal.

[20]  Cameron Y. S. Lee.  Medication-Related Osteonecrosis of the Jaw with the mTOR Inhibitor Everolimus in a Patient with Estrogen-Receptor Positive Breast Cancer: A Case Report , 2016 .

[21]  B. Turner,et al.  Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success , 2016, BioEssays : news and reviews in molecular, cellular and developmental biology.

[22]  A. Grauer,et al.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.

[23]  C. Proud,et al.  mTOR inhibitors in cancer therapy , 2016, F1000Research.

[24]  P. Enzinger,et al.  Osteonecrosis of the jaw associated with ziv-aflibercept. , 2016, Journal of gastrointestinal oncology.

[25]  D. Santini,et al.  RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw. , 2016, Journal of the National Cancer Institute.

[26]  H. Gharwan,et al.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications , 2016, Nature Reviews Clinical Oncology.

[27]  A. Vissink,et al.  Effect of leaving chronic oral foci untreated on infectious complications during intensive chemotherapy , 2016, British Journal of Cancer.

[28]  A. Polimeni,et al.  Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? , 2016, Case reports in dentistry.

[29]  S. Minucci,et al.  Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia , 2016, British Journal of Cancer.

[30]  L. Lesko,et al.  Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS) , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  R. Carpenter,et al.  Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors , 2016, Cancers.

[32]  F. di Costanzo,et al.  Regorafenib Also Can Cause Osteonecrosis of the Jaw. , 2016, Journal of the National Cancer Institute.

[33]  S. Gandolfo,et al.  Osteonecrosis of the jaw in a patient receiving cabozantinib. , 2015, Australian dental journal.

[34]  W. Park,et al.  Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. , 2015, Oral surgery, oral medicine, oral pathology and oral radiology.

[35]  C. Scully,et al.  Orofacial adverse effects of biological agents. , 2015, Journal of investigative and clinical dentistry.

[36]  R. H. Scofield,et al.  Biological therapy and dentistry: a review paper. , 2015, Oral surgery, oral medicine, oral pathology and oral radiology.

[37]  Jian Ding,et al.  PI3K isoform-selective inhibitors: next-generation targeted cancer therapies , 2015, Acta Pharmacologica Sinica.

[38]  M. McGurk,et al.  New cancer therapies and jaw necrosis , 2015, BDJ.

[39]  B. Fuchs,et al.  Hedgehog Signaling Inhibitors as Anti-Cancer Agents in Osteosarcoma , 2015, Cancers.

[40]  A. Polimeni,et al.  Periodontal disease and cancer patients undergoing chemotherapy. , 2015, International dental journal.

[41]  Yu Jiang,et al.  mTOR Inhibitors at a Glance. , 2015, Molecular and cellular pharmacology.

[42]  S. Zappavigna,et al.  ANTI CANCER DRUGS USED FOR TARGETED THERAPY , 2015 .

[43]  T. Dodson,et al.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[44]  M. Gossell-Williams,et al.  Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. , 2014, The West Indian medical journal.

[45]  A. Allegra,et al.  Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. , 2014, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[46]  D. Mazzoleni,et al.  Rituximab And Osteonecrosis of The Jaws: Case Study , 2014 .

[47]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[48]  E. Van Cutsem,et al.  Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. , 2014, European journal of cancer.

[49]  H. Park,et al.  Osteonecrosis of the jaw related to everolimus: a case report. , 2013, The British journal of oral & maxillofacial surgery.

[50]  M. Burke,et al.  The oral management of oncology patients requiring radiotherapy, chemotherapy and/or bone marrow transplantation , 2013 .

[51]  S. Schmidt,et al.  Fusion protein technologies for biopharmaceuticals : applications and challenges , 2013 .

[52]  S. Schmidt.  Fusion Proteins: Applications and Challenges , 2013 .

[53]  G. Campisi,et al.  Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? , 2013, Annali di stomatologia.

[54]  O. Beirne,et al.  The relationship of denosumab pharmacology and osteonecrosis of the jaws. , 2012, Oral surgery, oral medicine, oral pathology and oral radiology.

[55]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[56]  F. Dammacco,et al.  Targeted therapies in cancer , 2018, Surgery (Oxford).

[57]  J. Dancey,et al.  Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. , 2011, Future oncology.

[58]  T. Takizawa,et al.  Role of GLI2 in the growth of human osteosarcoma , 2011, The Journal of pathology.

[59]  T. Curran,et al.  The Hedgehog's tale: developing strategies for targeting cancer , 2011, Nature Reviews Cancer.

[60]  L. Crawford,et al.  Proteasome inhibitors in cancer therapy , 2011, Journal of Cell Communication and Signaling.

[61]  Neal Rosen,et al.  Targeted cancer therapies , 2011, Chinese journal of cancer.

[62]  S. Ruggiero.  Risk of osteonecrosis of the jaw and the use of bone targeted therapies , 2011 .

[63]  C. Esteve,et al.  Dental treatment considerations in the chemotherapy patient , 2011 .

[64]  S. Bates,et al.  Clinical Toxicities of Histone Deacetylase Inhibitors , 2010, Pharmaceuticals.

[65]  N. Robert,et al.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer , 2010, Breast Cancer Research and Treatment.

[66]  Hans-Peter Lipp,et al.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. , 2009, Current drug metabolism.

[67]  D. Burr,et al.  The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[68]  P. Elliott,et al.  Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts , 2002, Molecular Cancer Therapeutics.

[69]  C. Estilo,et al.  Osteonecrosis of the jaw related to bevacizumab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  D. McConkey,et al.  Mechanisms of proteasome inhibitor action and resistance in cancer. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[71]  R. Pazdur,et al.  United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy , 2006, Clinical Cancer Research.

[72]  E. Scholar,et al.  Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.

[73]  H. Lane,et al.  Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. , 2004, Bone.

[74]  M. Paul,et al.  Tyrosine kinase – Role and significance in Cancer , 2004, International journal of medical sciences.

[75]  J. Mccoy,et al.  Introduction to Expression by Fusion Protein Vectors , 1994, Current protocols in molecular biology.

[76]  M. Kumegawa,et al.  Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts , 2000, FEBS letters.

[77]  R. Prielipp,et al.  Clinical guidelines , 2003, BMJ.

[78]  J. Stoker,et al.  The Department of Health and Human Services. , 1999, Home healthcare nurse.

[79]  K. Shinohara,et al.  Apoptosis induction resulting from proteasome inhibition. , 1996, The Biochemical journal.

[80]  R. Gorlin,et al.  Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. , 1960, The New England journal of medicine.

[81]  John Millar Carroll.  Nadir , 1940 .